Stock DICE DICE THER
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

DICE THER

Equities

DICE

US23345J1043

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about DICE THER

S&P 500 Edges Down Weekly as US Consumer Prices Moved Modestly Higher in July, Technology, Materials Weigh MT
Global markets live: Allianz, Generali, Sony, Disney, Alibaba... Our Logo
Trending : Lilly Gets Price Target Increases, Closes DICE Purchase DJ
Eli Lilly Completes Acquisition of DICE Therapeutics MT
Eli Lilly Wraps Up Acquisition of Dice Therapeutics MT
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from NASDAQ Composite Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P Pharmaceuticals Select Industry Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P Global BMI Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P TMI Index CI
Eli Lilly and Company completed the acquisition of DICE Therapeutics, Inc. from a group of shareholders. CI
DICE Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from NASDAQ Biotechnology Index CI
Eli Lilly Extends Tender Offer to Acquire DICE Therapeutics to Aug. 9 MT
Eli Lilly Extends $2.4 Billion Tender Offer to Buy DICE Therapeutics MT
MoonLake Immunotherapeutics explores sale-sources RE
North American Morning Briefing : Stock Futures -2- DJ
Needham Downgrades DICE Therapeutics to Hold From Buy MT
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell 3000E Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell Microcap Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell Microcap Value Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell 3000E Value Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) added to Russell 3000E Growth Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) added to Russell 2500 Growth Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) added to Russell 3000 Growth Index CI
DICE Therapeutics, Inc.(NasdaqGM:DICE) added to Russell Small Cap Comp Growth Index CI

Chart DICE THER

Chart DICE THER
More charts

Company Profile

DICE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing oral therapeutics against well-validated targets in immunology. The Company's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The Company's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. DICE Stock
  4. News DICE THER
  5. SVB Securities Downgrades DICE Therapeutics to Market Perform Rating From Outperform, Adjusts Price Target to $48 From $77